Monopar Therapeutics Inc.
MNPRHealthcare|Biotechnology|US
$71.42
+4.20 (+6.25%)
DCF Value
$7.99
Tangible Book / Share
$15.32
Cash / Share
$15.72
Financials
Financial Snapshot
Market Cap
$479.4M
Enterprise Value
$426.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$17.8M
Cash & Investments
$134.3M
Net Cash
$134.2M
Free Cash Flow (TTM)
-$3.26B
Operating CF (TTM)
-$3.26B
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$134.3M
Quarterly Burn
$814.1M
Monthly Burn
$271.4M
Est. Runway
~0.2 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.1M | $9.0M | $6.9M | $13.2M | $16.7M | $20.3M | $13.1M | $7.3M | $60.2M | $140.4M | $134.3M | |
| Operating Cash Flow | -$1.2M | -$2.6M | -$2.9M | -$3.0M | -$4.7M | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M | -$3.26B | |
| Free Cash Flow | -$1.2M | -$2.6M | -$2.9M | -$3.0M | -$4.7M | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M | -$3.26B | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.00 | |
| Financing Cash Flow | $1.3M | $9.5M | -$206.3K | $9.3M | $8.2M | $10.9M | $32.9K | $2.0M | $59.3M | $91.6M | -$555.6M |
R&D Spending
R&D (TTM)
$14.8M
R&D Intensity
—
R&D Growth vs Prior
-99.9%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $280.4K | $935.3K | $1.8M | $2.0M | $4.1M | $6.5M | $7.6M | $5.6M | $13.0M | $9.90B | $14.8M | |
| SG&A | $912.5K | $1.2M | $1.6M | $2.4M | $2.4M | $2.6M | $2.9M | $3.2M | $3.2M | $6.80B | $1.74B |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $280.4K | $935.3K | $1.8M | $2.0M | $4.1M | $6.5M | $7.6M | $5.6M | $13.0M | $9.90B | $14.8M | |
| SG&A | $912.5K | $1.2M | $1.6M | $2.4M | $2.4M | $2.6M | $2.9M | $3.2M | $3.2M | $6.80B | $1.74B | |
| Operating Income | -$1.2M | -$16.6M | -$3.4M | -$4.3M | -$6.5M | -$9.1M | -$10.5M | -$8.8M | -$16.2M | -$16.7M | -$22.1M | |
| Interest Expense | $7.2K | $48.3K | $103.2K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$1.2M | -$16.6M | -$3.3M | -$4.2M | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M | -$17.8M | |
| Net Income | -$1.2M | -$16.6M | -$3.2M | -$4.2M | -$6.3M | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M | -$17.8M | |
| EPS (Diluted) | -0.12 | -1.59 | -0.31 | -0.40 | -0.58 | -0.73 | -0.83 | -0.58 | -1.36 | -1.85 | -2.34 | |
| EBITDA | $8.0K | -$14.5M | $147.00 | -$4.2M | $0.00 | -$9.1M | -$10.5M | -$8.4M | -$15.6M | -$13.7M | -$18.5M | |
| Shares Out. (M) | 9.86 | 10.42 | 10.42 | 10.59 | 10.96 | 12.47 | 12.72 | 14.51 | 11.48 | 7.41 | 8.54 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.1M | $9.0M | $6.9M | $13.2M | $16.7M | $20.3M | $8.2M | $7.3M | $45.8M | $61.8M | $52.8M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $4.9M | $0.00 | $14.4M | $78.6M | $81.5M | |
| Total Current Assets | $2.1M | $9.1M | $7.3M | $13.2M | $16.8M | $20.5M | $13.2M | $7.3M | $60.3M | $140.5M | $134.8M | |
| Total Assets | $2.9M | $9.9M | $7.3M | $13.4M | $16.9M | $20.5M | $13.2M | $7.3M | $60.3M | $140.7M | $135.0M | |
| Total Current Liabilities | $64.5K | $311.9K | $399.6K | $724.2K | $1.2M | $1.6M | $3.1M | $1.8M | $5.3M | $2.7M | $4.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $64.5K | $311.9K | $399.6K | $724.2K | $1.2M | $1.6M | $3.1M | $1.8M | $5.3M | $2.9M | $4.1M | |
| Stockholders' Equity | $2.8M | $9.6M | $6.9M | $12.6M | $15.7M | $18.9M | $10.1M | $5.6M | $55.0M | $137.8M | $130.9M | |
| Retained Earnings | -$1.9M | -$18.4M | -$21.7M | -$25.9M | -$32.2M | -$41.3M | -$51.8M | -$60.2M | -$75.8M | -$89.5M | -$98.7M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$2.6M | -$2.9M | -$3.0M | -$4.7M | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M | -$3.26B | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.00 | |
| Free Cash Flow | -$1.2M | -$2.6M | -$2.9M | -$3.0M | -$4.7M | -$7.3M | -$7.2M | -$7.9M | -$6.4M | -$12.2M | -$3.26B | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.9M | $4.9M | -$14.3M | -$63.5M | $4.05B | |
| Financing Cash Flow | $1.3M | $9.5M | -$206.3K | $9.3M | $8.2M | $10.9M | $32.9K | $2.0M | $59.3M | $91.6M | -$555.6M | |
| Issuance of Stock | $1.3M | $4.7M | -$206.3K | $10.2M | $8.2M | $10.9M | $109.3K | $2.1M | $59.4M | $127.7M | $135.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$35.0M | -$35.2M | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $122.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $305.2K | $529.3K | $1.0M | $1.3M | $1.5M | $1.6M | $1.9M | $1.1M | $4.8M | $1.43B | |
| Net Change in Cash | $67.9K | $6.9M | -$2.9M | $6.3M | $3.5M | $3.6M | -$12.1M | -$920.1K | $38.6M | $16.0M | $226.5M |
Dilution Tracker
Shares Outstanding
7M
5-Year Share Growth
-32.4%
Stock Issuance (TTM)
$135.3M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 9.86 | 10.42 | 10.42 | 10.59 | 10.96 | 12.47 | 12.72 | 14.51 | 11.48 | 7.41 | 8.54 | |
| Change vs Prior % | — | 5.7% | 0.0% | 1.6% | 3.5% | 13.8% | 2.0% | 14.1% | -20.9% | -35.5% | 15.3% | |
| Stock Issuance | $1.3M | $4.7M | -$206.3K | $10.2M | $8.2M | $10.9M | $109.3K | $2.1M | $59.4M | $127.7M | $135.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$35.0M | -$35.2M | |
| Stock Based Comp. | $0.00 | $305.2K | $529.3K | $1.0M | $1.3M | $1.5M | $1.6M | $1.9M | $1.1M | $4.8M | $1.43B |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | -41.9% | -172.1% | -46.7% | -33.5% | -40.2% | -48.1% | -104.2% | -150.4% | -28.3% | -10.0% | -13.1% | |
| ROA % | -40.9% | -166.7% | -44.1% | -31.6% | -37.4% | -44.4% | -79.5% | -114.4% | -25.9% | -9.7% | -13.2% | |
| ROIC % | -42.1% | -172.6% | -45.4% | -34.2% | -41.5% | -48.2% | -104.3% | -158.0% | -29.4% | -12.1% | -16.9% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | -73.1% | -1291.9% | 79.5% | -27.1% | -50.5% | -40.2% | -15.4% | 16.2% | -83.0% | -3.4% | |
| Net Income | -72.6% | -1296.3% | 80.5% | -30.9% | -49.2% | -44.4% | -15.5% | 20.1% | -85.5% | 12.0% | |
| EPS (Diluted) | -42.5% | -1225.0% | 80.5% | -29.0% | -45.0% | -25.9% | -13.7% | 30.1% | -134.5% | -36.0% | |
| Operating Cash Flow | -87.7% | -119.9% | -9.9% | -4.5% | -54.5% | -56.9% | 1.2% | -8.7% | 18.5% | -90.5% | |
| Free Cash Flow | -87.7% | -119.9% | -9.9% | -4.5% | -54.5% | -56.9% | 1.2% | -8.7% | 18.5% | -90.5% | |
| R&D Expense | 176.2% | 233.6% | 89.7% | 11.0% | 106.5% | 59.7% | 16.9% | -26.2% | 132.2% | 76051.3% | |
| SG&A Expense | 55.4% | 27.8% | 39.6% | 44.7% | 3.8% | 7.8% | 11.8% | 9.7% | -2.3% | 215386.7% | |
| Total Assets | 2.4% | 243.0% | -26.3% | 82.5% | 26.3% | 21.7% | -35.5% | -44.5% | 720.8% | 133.4% | |
| Book Value / Share | -14.9% | 221.3% | -28.1% | 79.6% | 20.1% | 6.1% | -47.8% | -51.5% | 1149.0% | 286.7% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | |
| Diluted Shares | 20.8% | 5.7% | 0.0% | 1.6% | 3.5% | 13.8% | 2.0% | 14.1% | -20.9% | -35.5% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B4.66
10Y Low / Med / High3.51 / 21.37 / 461.24
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$7.99
Tangible Book / Share
$15.32
Net Current Assets / Share
$19.46
Graham Net-Net
$15.24
Cash / Share
$15.72
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -1104.17 | -83.33 | -427.42 | -207.50 | -52.76 | -21.99 | -14.28 | -2.93 | -16.18 | -35.30 | -30.52 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 461.24 | 143.54 | 199.58 | 69.59 | 21.37 | 10.57 | 14.94 | 4.41 | 4.57 | 3.51 | 4.66 | |
| EV/EBITDA | 162314.97 | -94.91 | 9346188.63 | -204.88 | 0.00 | -19.76 | -13.55 | -2.07 | -13.21 | -30.78 | -23.07 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
69.43
Safe
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $400.0K | $27.9M | $84.7M |
| Net Income | -$23.1M | -$19.0M | -$24.9M |
| EPS | $-2.98 | $-2.46 | $-1.86 |
| # Analysts (EPS) | 8 | 7 | 7 |